Paediatric ARV
dosing dashboard
Drug dosing tool for prescribing
antiretroviral medications to infants
and children
The WHO Paediatric ARV dosing dashboard aims to support health care workers, researchers and policy makers in decisions around ARV dosing for children. It includes a dosing tool to assist in selecting the correct dose for infants, children and adolescents less than 18 years of age, background information to support WHO paediatric weight-band dosing recommendations for ARV drugs, and a tool for researchers who may want to investigate various ARV dosages and calculate the expected drug exposure in children relative to adult targets after administration of various doses.
The dosing tool generates an advice for the preferred ARVs combinations, preferred formulation, and recommended dose based on the child’s weight, age, swallowing capability, concomitant use of TB treatment, gestational age (only for neonates), and previous medications used (only for 2nd line treatment). The dose recommendations are based on the WHO paediatric dosing annex and reflect the dosing recommendations of the Paediatric ARV Working Group (PAWG).
With the introduction of harmonized paediatric weight-band dosing for ARVs, some WHO dose recommendations deviate from the manufacturer’s package insert. The background information pages include the scientific rationale and considerations behind the WHO recommended doses in case these deviate from the manufacturer’s package insert. The pages also include information about knowledge gaps, considerations with regards to formulations, frequently occurring drug-drug interactions, and other important information with regards to dosing.
In some instances, it is useful to investigate the expected exposure in children with a single or fixed-dose combination in more detail and compare this with the expected exposures found in adults. The WHO Generic Tool App can assist you in making evidence-based decisions when exploring (new) formulations by predicting relative exposures compared to an (adult) reference.
This tool will be periodically updated to reflect new evidence and new dosing recommendations as those become available.
Child's
Age
Date
of Birth
Weight
. kg
Rounded to 1 Decimal
What was the gestational age at birth?
< 35 weeks
> 35 weeks / unknown
-
coming soon
coming soon
First line treatment:
No treatment failure and no suspected treatment failure on previous antiretroviral therapy.Second line treatment:
Known treatment failure or suspected treatment failure on previous antiretroviral therapy.
Generate dose advice for
HIV treatment or high risk preventionGenerate dose advice for
low risk HIV prevention
Select one of the options in this table to generate a dosing advice
| Preferred ARVs | AZT + 3TC + NVP |
| Preferred Regimen | AZT + 3TC + RAL |
| Alternative Regimen | AZT + 3TC + NVP |
| Special Circumstances | AZT + 3TC + LPVr |
| Drug | Strength | 0-6 week | 6-12 weeks | 12 weeks to 6 months | 9 months to 24 months | ||||
| AM | PM | AM | PM | AM | PM | AM | PM | ||
| NVPa | 50 mg score dispersible tablets |
0.5 | — | 0.5 | — | 0.5 | — | 1 | — |
| NVP | 10 mg/ml | 1.5 mL | — | 2 mL | — | 3 mL | — | 4 mL | — |
| AZT | 10 mg/ml | 1.5 mL | 1.5 mL | 6 mL | 6 mL | — | — | — | — |
| To avoid dose changes over a short period of time and to minimize the likelihood of errors, all ARV drugs except for RAL (dose change after week 1), should be dosed based on weight when treatment starts and maintained until four weeks of age (weight gain is limited during the first four weeks of life). |
| This simplified dosing was developed with WHO generic tool based on known NVP prophylactic targets. |
| Preferred Regimen | ABC + 3TC + DTG | |||||||
| Alternative Regimen |
|
|||||||
| Special Circumstances |
|
Dosage:
AZT + 3TC + NVP
Please consult with specialist for the appropriate dose
Formulation:
ABC + 3TC + LPVr
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Lopinavir (LPV)/ritonavir(RTV) | Raltegravir Oral liquid 10 mg/ml | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Lopinavir (LPV)/ritonavir(RTV) | - | - | - |
Formulation:
TAF + 3TC + DTG
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Tenofovir alafenamide (TAF) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Dolutegravir (DTG) | Filmcoated tablets - 50 mg | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Tenofovir alafenamide (TAF) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Dolutegravir (DTG) | - | - | - |
Formulation:
TAF + FTC + DTG
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Tenofovir alafenamide (TAF) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Emtricitabine (FTC) | Oral liquid 10mg/mL | 10 ml | BID |
| Dolutegravir (DTG) | Filmcoated tablets - 50 mg | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Tenofovir alafenamide (TAF)/td> | - | - | - |
| Emtricitabine (FTC) | - | - | - |
| Dolutegravir (DTG)) | - | - | - |
Formulation:
ABC + 3TC + RAL
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Raltegravir (RAL) | Raltegravir Oral liquid 10 mg/ml | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Raltegravir (RAL) | - | - | - |
Formulation:
ABC + 3TC + EFV
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Efavirenz (EFV) | Raltegravir Oral liquid 10 mg/ml | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Efavirenz (EFV) | - | - | - |
Formulation:
ABC + 3TC + NVP
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Nevirapine (NVP) | Raltegravir Oral liquid 10 mg/ml | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Nevirapine (NVP) | - | - | - |
Formulation:
AZT + 3TC + EFV
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Efavirenz (EFV) | Tablet (scored) - 200 mg | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Efavirenz (EFV) | - | - | - |
Formulation:
AZT + 3TC + NVP
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Nevirapine (NVP) | Oral solution 50 mg/5 mL | 50 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Nevirapine (NVP) | - | - | - |
Formulation:
AZT + 3TC + LPVr
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Lopinavir (LPV)/ritonavir(RTV) | - | - | - |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Lopinavir (LPV)/ritonavir(RTV) | - | - | - |
Formulation:
AZT + 3TC + RAL
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Raltegravir (RAL) | Raltegravir Oral liquid 10 mg/ml | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Raltegravir (RAL) | - | - | - |
Select one of the options in this table to generate a dosing advice
| Regimen |
| ABC + 3TC + DTG |
| ABC + 3TC + LPVr |
| ABC + 3TC + ATVr |
| AZT + 3TC + DTG |
| AZT + 3TC + LPVr |
| AZT + 3TC + ATVr |
| TAF + 3TC + DTG |
| TAF + 3TC + LPVr |
| TAF + 3TC + ATVr |
Formulation:
ABC + 3TC + DTG
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Dolutegravir (DTG) | Dispersible tablets (scored) - 10 mg | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Dolutegravir (DTG) | - | - | - |
Formulation:
ABC + 3TC + LPVr
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Lopinavir (LPV)/ritonavir(RTV) | Raltegravir Oral liquid 10 mg/ml | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Lopinavir (LPV)/ritonavir(RTV) | - | - | - |
Formulation:
TAF + 3TC + DTG
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Tenofovir alafenamide (TAF) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Dolutegravir (DTG) | Filmcoated tablets - 50 mg | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Tenofovir alafenamide (TAF) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Dolutegravir (DTG) | - | - | - |
Formulation:
TAF + FTC + DTG
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Tenofovir alafenamide (TAF) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Emtricitabine (FTC) | Oral liquid 10mg/mL | 10 ml | BID |
| Dolutegravir (DTG) | Filmcoated tablets - 50 mg | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Tenofovir alafenamide (TAF)/td> | - | - | - |
| Emtricitabine (FTC) | - | - | - |
| Dolutegravir (DTG)) | - | - | - |
Formulation:
ABC + 3TC + RAL
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Raltegravir (RAL) | Raltegravir Oral liquid 10 mg/ml | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Raltegravir (RAL) | - | - | - |
Formulation:
ABC + 3TC + EFV
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Efavirenz (EFV) | Raltegravir Oral liquid 10 mg/ml | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Efavirenz (EFV) | - | - | - |
Formulation:
ABC + 3TC + NVP
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Nevirapine (NVP) | Raltegravir Oral liquid 10 mg/ml | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Abacavir (ABC) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Nevirapine (NVP) | - | - | - |
Formulation:
AZT + 3TC + EFV
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Efavirenz (EFV) | Tablet (scored) - 200 mg | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Efavirenz (EFV) | - | - | - |
Formulation:
AZT + 3TC + NVP
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Nevirapine (NVP) | Oral solution 50 mg/5 mL | 10 ml | BID |
| Raltegravir (RAL) | Raltegravir Oral liquid 10 mg/ml | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Nevirapine (NVP) | - | - | - |
Formulation:
AZT + 3TC + LPVr
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Lopinavir (LPV)/ritonavir(RTV) | - | - | - |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Lopinavir (LPV)/ritonavir(RTV) | - | - | - |
Formulation:
AZT + 3TC + RAL
| ARV | Preferred Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | Oral granules for suspension 100mg/sachet – 10mg/ml | 3 ml | BID |
| Lamivudine (3TC) | Oral liquid 10mg/mL | 10 ml | BID |
| Raltegravir (RAL) | Raltegravir Oral liquid 10 mg/ml | 3 ml | BID |
| ARV | Alternative Formulation | Amount | Frequency |
|---|---|---|---|
| Zidovudine (AZT) | - | - | - |
| Lamivudine (3TC) | - | - | - |
| Raltegravir (RAL) | - | - | - |
WHO Generic Dosing Tool
The WHO generic dosing tool can predict relative exposure compared to an (adult) reference. Because it utilizes the general principles of the relation between body size and age with exposure it can predict this for any drug. The background, features and technical specifications are published in The Lancet Child and Adolescent Health (Denti P, Wasmann RE, Francis J, et al. 2021).
Download the WHO Generic Dosing Tool
The tool can be adapted to the specific drug under investigation. In the first tab, the user defines the reference adult exposure, which will be used as a target. The tool automatically calculates this reference value based on the body weight and daily dose administered to a reference adult patient. Additionally, the tool requires the strength of the available or planned paediatric formulation.
The tool can analyse up to 4 drugs at the same time within a single formulation, which is applicable for the majority of FDCs. In the second tab, the user defines the dosing regimen they wish to explore by choosing the number of tablets administered in each weight-band. Alternatively, in the third tab, kg-by-kg steps can be used to define customised weight-bands more granularly.
After all settings have been entered, the tool predicts exposure at steady-state relative to the values achieved for the reference adult over the same dosing interval. The tool assumes similar bioavailability between children and adults and first-order elimination, i.e., the clearance is constant within the relevant concentration range, with no significant saturable elimination processes. It uses allometric scaling to adjust for the non-linear effect of body size on clearance and its subsequent effect onto the exposure, which is used to compare children and adults. For each weight-band, the tool graphically displays the value of the expected relative exposure in the child with the smallest and largest weight.
A. Input the target dose per drug in adults
The target exposure in children is the same as an adult receiving
| Drug 1 | 600 | mg daily | |||
| Drug 2 | 600 | mg daily | |||
| Drug 3 | 300 | mg daily | |||
| Drug 4 | 300 | mg daily | |||
B. Input the reference adults weight
The reference★ weight for an adult is here taken to be
- 40
- kg
| This implies that the reference adult receives: | |||||
|---|---|---|---|---|---|
| Drug 1 | 15 | mg/kg | |||
| Drug 2 | 15 | mg/kg | |||
| Drug 3 | 7.5 | mg/kg | |||
| Drug 4 | 7.5 | mg/kg | |||
C. Set the strength of each component in the fixed dose combination
Target Fixed Dose Combination to explore Each tablet contains:
| Drug 1 | 80 | mg |
| Drug 2 | 60 | mg |
| Drug 3 | 35 | mg |
| Drug 4 | 50 | mg |
D. Set the acceptable exposure range
The acceptable range for median exposure (WRT the refence adult) is
| Drug 1 | from | 80% | to | 125% |
| Drug 2 | from | 80% | to | 125% |
| Drug 3 | from | 80% | to | 125% |
| Drug 4 | from | 80% | to | 125% |
E. Optionally, specify a maturation function, which will be plotted on the right
(Optional/Experimental)
Include maturation of clearance? Yes
| Settings | Drug 1 | Drug 2 | Drug 3 | Drug 4 | |
|---|---|---|---|---|---|
| AGE 50%** | 1.5 | 4.37 | 1.32 | -9 | (months from term birth) |
| Gamma | 4.37 | 3.02 | 2.6 | 1 | (unitless) |
Exposure by WHO weight bands
Choose the number of tablets per weight band
| WHO Weight bands | |||
| Weight-band | Lower bound | Upper bound | |
| 3 - 5.9 | 3 | 5.9 | |
| 6 - 9.9 | 6 | 9.9 | |
| 10 - 13.9 | 10 | 13.9 | |
| 14 - 19.9 | 14 | 19.9 | |
| 20 - 24.9 | 20 | 24.9 | |
| 25 - 34.9 | 25 | 34.9 | |
| # of tablets |
|---|
| 1 |
| 2 |
| 3 |
| 4 |
| 5 |
| 6 |
The predicted equivalent exposure of the largest and smallest child per weight band is displayed in a graph
And also in table form
| Total dose achieved | Smallest Child | Largest Child | Smallest Child Exposure | Largest Child Exposure | Equivalent high | Equivalent low |
| mg | mg/kg | mg/kg | (AUC) | (AUC) | mg/kg | mg/kg |
| 80 | 26.7 | 13.6 | 0.93 | 0.56 | 13.96 | 8.40 |
| 160 | 26.7 | 16.2 | 1.11 | 0.76 | 16.60 | 11.40 |
| 240 | 24.0 | 17.3 | 1.13 | 0.88 | 16.97 | 13.26 |
| 320 | 22.9 | 16.1 | 1.17 | 0.90 | 17.58 | 13.51 |
| 400 | 20.0 | 16.1 | 1.12 | 0.95 | 16.82 | 14.27 |
| 480 | 19.2 | 13.8 | 1.14 | 0.89 | 17.07 | 13.29 |
Exposure by custom weight bands
Choose the number of tablets per weight band
| WHO Weight bands (colour-coded) | |||
| Weight-band | Lower bound | Upper bound | |
| 3 - 3.9 | 3 | 3.9 | |
| 4 - 4.9 | 4 | 4.9 | |
| 5 - 5.9 | 5 | 5.9 | |
| 6 - 6.9 | 6 | 6.9 | |
| 7 - 7.9 | 7 | 7.9 | |
| 8 - 8.9 | 8 | 8.9 | |
| 9 - 9.9 | 9 | 9.9 | |
| 10 - 10.9 | 10 | 10.9 | |
| 11 - 11.9 | 11 | 11.9 | |
| 12 - 12.9 | 12 | 12.9 | |
| 13 - 13.9 | 13 | 13.9 | |
| 14 - 14.9 | 14 | 14.9 | |
| 15 - 15.9 | 15 | 15.9 | |
| 16 - 16.9 | 16 | 16.9 | |
| 17 - 17.9 | 17 | 17.9 | |
| 18 - 18.9 | 18 | 18.9 | |
| # of tablets |
|---|
| 1 |
| 1.5 |
| 2 |
| 2 |
| 2 |
| 2 |
| 2 |
| 3 |
| 3 |
| 3 |
| 3 |
| 4 |
| 4 |
| 4 |
| 4 |
| 4 |
| WHO Weight bands (colour-coded) | |||
| Weight-band | Lower bound | Upper bound | |
| 19 - 19.9 | 19 | 19.9 | |
| 20 - 20.9 | 20 | 20.9 | |
| 21 - 21.9 | 21 | 21.9 | |
| 22 - 22.9 | 22 | 22.9 | |
| 23 - 23.9 | 23 | 23.9 | |
| 24 - 24.9 | 24 | 24.9 | |
| 25 - 25.9 | 25 | 25.9 | |
| 26 - 26.9 | 26 | 26.9 | |
| 27 - 27.9 | 27 | 27.9 | |
| 28 - 28.9 | 28 | 28.9 | |
| 29 - 29.9 | 29 | 29.9 | |
| 30 - 30.9 | 30 | 30.9 | |
| 31 - 31.9 | 31 | 31.9 | |
| 32 - 32.9 | 32 | 32.9 | |
| 33 - 33.9 | 33 | 33.9 | |
| 34 - 34.9 | 34 | 34.9 | |
| # of tablets |
|---|
| 4 |
| 5 |
| 5 |
| 5 |
| 5 |
| 5 |
| 6 |
| 6 |
| 6 |
| 6 |
| 6 |
| 6 |
| 6 |
| 6 |
| 6 |
| 6 |
The predicted equivalent exposure will be outputted as graphs and tables for the largest and smallest child per weight band
Acknowledgements
The work to develop and update the WHO Paediatric ARV dosing dashboard has been conducted in collaboration with the Paediatric Antiretroviral Working Group, Radboud university medical center, University of Cape Town, and PENTA.
Development team: Tom Jacobs, Hylke Waalewijn, Angela Colbers from the Radboud university medical centre, Nijmegen, the Netherlands with input from WHO staff Martina Penazzato and Asma Hafiz.
We also thank experts from the Paediatric Antiretroviral Working Group (PAWG) who were consulted in the drafting of the background information on each ARV and testing of the tool: Anna Turkova, Brookie Best, Diana Clarke, Elaine Abrams, Lynne Mofenson, Mark Mirochnick, Natella Rakhmanina, Pablo Rojo, Paolo Denti, Theodore Ruel, Tim Cressey, and team PATA.
The WHO Generic Dosing Tool was developed by Paolo Denti, Roeland Wasmann, Jose Francis from the University of Cape Town, Cape Town, South Africa with input from Helen McIlleron, Nandita Sugandhi, Tim Cressey, Mark Mirochnick, Edmund Capparelli, Martina Penazzato and the Paediatric Antiretroviral Working Group (PAWG)
Other Links